0
Your cart

Your cart is empty

Books > Science & Mathematics > Biology, life sciences > Life sciences: general issues > Neurosciences

Buy Now

Imaging and Multiomic Biomarker Applications (Hardcover) Loot Price: R3,466
Discovery Miles 34 660
Imaging and Multiomic Biomarker Applications (Hardcover): Yongxia Zhou

Imaging and Multiomic Biomarker Applications (Hardcover)

Yongxia Zhou

 (sign in to rate)
Loot Price R3,466 Discovery Miles 34 660 | Repayment Terms: R325 pm x 12*

Bookmark and Share

Expected to ship within 12 - 19 working days

The well-known Alzheimer's Disease Neuroimaging Initiative (ADNI) Center provides the most advanced, comprehensive, multiparametric and up-to-date biomarkers for mild cognitive impairment (MCI) and early Alzheimer's disease (AD) projects, including neuroimaging, clinical assessments, biospecimens and genetic data. Recent developments in imaging techniques, including new molecular tracers for imaging disease burden and systematic multi-modal integration, have emerged to overcome the limitations of each single modality and individual-dependent variability. The MRI-based high-resolution structural and morphological changes in the brain, such as atrophy, and the abnormal activity/connectivity patterns of the hippocampus subfields and default mode network (DMN) modulation, together with the amyloid and tau neuropathological quantification using PET molecular tracers, could be used to predict brain changes and cognitive performance declines in early AD, including transitional MCI. Finally, a generalized and integrative model with multiple biomarkers could be built to target disease progression and symptom prediction as well as to optimize patient management. Multiomics investigates metabolomic, lipidomic, genomic, transcriptomic and proteomic perspectives by presenting an accurate biochemical profile of the organism in health and disease. The Alzheimer's Disease Metabolomics Consortium (ADMC) in partnership with ADNI is creating a comprehensive biochemical database for patients in the ADNI1 cohort, consisting of eight metabolomics datasets. The vast majorities of biospecimen data provide rich biological information to the human brain at normal and dementia status. One of the purposes is to reveal the connections between disease and multiomics such as obesity, hypertension, cholesterol imbalance and inflammation risks that might lead to neurodegenerative disease. Multiomic biomarker developments in the dementia field have provided earlier clues to novel treatments that help correct metabolic dysfunction and delay disease progression. Furthermore, the assembling of multiomics-based biomarkers including metabolites and lipids, cholesterol biosynthesis, purine metabolism, lipoprotein, bile acids, and genetics as well as their relation to the pathological amyloid and tau network could improve disease diagnosis sensitivity and reveal more diverse and complementary molecular pathways to allow for the advancement of early AD diagnosis and therapeutic prevention. In this book, we report on the significant differences of multiple biomarkers from the ADNI database including neuroimaging, clinical assessments and multiomic biospecimen/genetic data in MCI and early probable AD (pAD), and elucidate the interconnections among different metrics at various domains. Classification results with high accuracies (0.95-1) for each early dementia subtype including early MCI (EMCI), late MCI (LMCI) and pAD, and better prediction of clinical symptoms is achieved with these comprehensive biomarkers. Further longitudinal changes of imaging and neuropsychological biomarkers, and inter-correlations with baseline parameters are examined for a better illustration of disease progression association. Additionally, an analysis of the post-traumatic stress disorder biomarkers is performed with high classification accuracy. With illustrative and rigorous data analyses and confirmative results, this book provides readers with a full spectrum of biomarker research for early dementia diagnosis and treatment, and helps convey the technical development and data evaluation perspectives in advanced medical imaging and various disease application fields.

General

Imprint: nova science publishers
Country of origin: United States
Release date: March 2021
Authors: Yongxia Zhou
Format: Hardcover
Pages: 251
ISBN-13: 978-1-5361-9079-3
Categories: Books > Science & Mathematics > Biology, life sciences > Life sciences: general issues > Neurosciences
Promotions
LSN: 1-5361-9079-9
Barcode: 9781536190793

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

You might also like..

The Awakened Brain - The Psychology Of…
Lisa Miller Paperback R334 R302 Discovery Miles 3 020
Encyclopedia of Sleep and Circadian…
Clete Kushida Hardcover R50,970 Discovery Miles 509 700
Introduction to Basic Aspects of the…
Otto Appenzeller, Guillaume J. Lamotte, … Hardcover R3,701 Discovery Miles 37 010
Neurological Complications of Systemic…
Herbert B. Newton, Mark G Malkin Hardcover R5,342 Discovery Miles 53 420
Neurobiology of Bipolar Disorder - Road…
Joao Luciano de Quevedo, Andre Ferrer Carvalho, … Paperback R4,287 Discovery Miles 42 870
The Senses: A Comprehensive Reference
Bernd Fritzsch Hardcover R93,914 Discovery Miles 939 140
Music and the Aging Brain
Lola Cuddy, Sylvie Belleville, … Paperback R3,226 Discovery Miles 32 260
Encyclopedia of Animal Behavior
Jae C. Choe Hardcover R43,860 Discovery Miles 438 600
Imagining the Brain: Episodes in the…
Chiara Ambrosio, William Maclehose Hardcover R6,579 Discovery Miles 65 790
Psychedelic Neuroscience, Volume 242
Tanya Calvey Hardcover R6,568 Discovery Miles 65 680
Genetic Models and Molecular Pathways…
Anantha Shekhar Hardcover R6,561 Discovery Miles 65 610
Imaging in Movement Disorders: Imaging…
Marios Politis Hardcover R4,804 Discovery Miles 48 040

See more

Partners